Is BPC-157 an FDA-approved medicine?
No. BPC-157 has never gone through FDA's new drug approval process, and nothing in the current record suggests an application is pending. FDA's May 2026 briefing document for its own advisory committee describes the compound as lacking adequate safety and effectiveness data to support even a narrower compounding pathway, let alone full approval, citing an absence of carcinogenicity studies and inadequate chemical characterisation [2].
Under the statutory drug definition, any product marketed with claims that it affects the structure or function of the body is legally treated as a drug regardless of what its label says [5]. A peptide sold as research use only but marketed for human therapeutic effects falls in the same unapproved-drug category as one sold outright for that purpose. Approval and legality of sale are not the same question, and BPC-157 fails the first one entirely.
Can a pharmacy legally compound BPC-157 in the US right now?
As of September 2026, no, though this part of its status is actively in motion. Compounding pharmacies operate under a separate legal pathway from full drug approval, requiring that a bulk substance comply with an applicable pharmacopoeia monograph and be manufactured at an FDA-registered facility [4]. FDA currently lists BPC-157 under nominated but withdrawn on its bulk-substances safety-risk page, a status unchanged when checked directly on 17 September 2026 [1].
FDA's own May 2026 briefing document concluded that the evidence weighs against placing either BPC-157 form on the compounding list [2]. Its Pharmacy Compounding Advisory Committee then met on 23 and 24 July 2026 and voted, by most published accounts 8 to 6, to recommend BPC-157 for the list anyway, against its own staff's assessment [3, 10]. A committee recommendation is not a rule change. No Federal Register notice or updated bulk-substances listing reflecting that vote has been located, meaning the legal compounding pathway remains closed pending further FDA action.
Is BPC-157 a scheduled controlled substance in the US?
No. A search of the DEA's current list of controlled substances, the August 2026 edition, found no mention of BPC-157 or its chemical name anywhere in the text [6]. This is a distinct legal question from FDA approval status.
A substance can be uncontrolled by the DEA and still be an unapproved new drug under FDA law at the same time, which is BPC-157's position. Its absence from the DEA's list has no bearing on whether a company can lawfully manufacture, market, or sell it for human use.
What is BPC-157's status under EU medicines law?
There is no EU-level authorisation and no registered EU clinical activity for BPC-157 at all. A search of the EU Clinical Trials Register returned zero matching trials as of 17 September 2026 [7]. A search of the European Medicines Agency's published assessment reports, the formal record of centrally authorised medicines, located no entry for BPC-157 [8].
This is a no-record-found result rather than an explicit EU statement that the substance is prohibited. The EU medicines framework generally has nothing to say about a substance until someone files for authorisation or registers a trial involving it, and no one has done either for BPC-157 at the EU level as of this date.
Does selling BPC-157 as 'research use only' change its legal status in either jurisdiction?
No. FDA's own regulations define intended use by objective evidence, including labelling claims, advertising, and other statements, not by the label alone [5]. A seller who markets BPC-157 for human therapeutic effects while stamping it research use only has not changed its legal category; the FDA's 2026 warning letters to peptide sellers over exactly this pattern confirm this is an active enforcement position, not a theoretical point.
The EU's medicinal-product framework works the same way: what a product is called does not decide what rules apply to it, its actual intended use does.
Is BPC-157's legal status the same as its status in competitive sport?
No, and this is a genuinely separate framework worth naming so it is not confused with drug law. The World Anti-Doping Agency's 2026 Prohibited List bans any substance with no current approval by a governmental regulatory health authority for human therapeutic use under category S0, at all times, and names BPC-157 as an example [9].
This ban applies to athletes under the WADA code regardless of what any single country's drug scheduling or compounding law says, and regardless of whether a US compounding pathway eventually opens. An athlete cannot rely on a future compounding rule change to make BPC-157 permissible in competition; the WADA ban is triggered by the same underlying fact, lack of approval for human therapeutic use, that also currently blocks US compounding and EU authorisation.
What would change this answer
An FDA final rule or Federal Register notice acting on the July 2026 committee vote would be the single biggest change to this answer. A filed EU marketing authorisation application or a newly registered EU clinical trial would change the EU section. Any DEA scheduling action would change the controlled-substance section, though nothing in the current record suggests one is under consideration.
Three questions to ask next
Has FDA published a Federal Register notice or updated bulk-substances list reflecting the July 2026 committee's compounding recommendation?
Have any individual EU member states adopted a national position on BPC-157 separate from the EU-wide absence of authorisation?
Has BPC-157 been the subject of any DEA scheduling petition or review, even if not yet reflected in the current published schedules?
Ask better questions.
- [1] Certain bulk drug substances that may present significant safety risks (BPC-157 status) (opens in new tab). FDA, current as of 22 April 2026, rechecked 17 September 2026Back to text (first mention of source 1)
- [2] FDA briefing document, Pharmacy Compounding Advisory Committee meeting on BPC-157 (opens in new tab). FDA, 11 May 2026Back to text (first mention of source 2)
- [3] Pharmacy Compounding Advisory Committee, 23 to 24 July 2026 (opens in new tab). FDA advisory committee calendarBack to text (first mention of source 3)
- [4] 21 U.S.C. 353a(b)(1)(A): 503A bulk substance conditions (opens in new tab). Cornell LIIBack to text (first mention of source 4)
- [5] 21 U.S.C. 321(g)(1)(B)-(C): statutory drug definition (opens in new tab). Cornell LIIBack to text (first mention of source 5)
- [6] DEA lists of scheduling actions, controlled substances and regulated chemicals (Orange Book) (opens in new tab). Drug Enforcement Administration, August 2026 editionBack to text (first mention of source 6)
- [7] EU Clinical Trials Register search: zero results for BPC-157 (opens in new tab). European Union / EMA, checked 17 September 2026Back to text (first mention of source 7)
- [8] EMA medicines search: no assessment report located for BPC-157 (opens in new tab). European Medicines Agency, checked 17 September 2026Back to text (first mention of source 8)
- [9] WADA 2026 Prohibited List, category S0 (opens in new tab). WADA, in force 1 January 2026Back to text (first mention of source 9)
- [10] Coverage of the July 2026 committee vote (8-6, against staff recommendation) (opens in new tab). Tech Times, 30 July 2026 SecondaryBack to text (first mention of source 10)